Cefuroxime: Difference between revisions
ClaireLewis (talk | contribs) |
|||
(19 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: 2nd generation [[cephalosporin]] | *Type: 2nd generation [[cephalosporin]] | ||
*Dosage Forms: PO | *Dosage Forms: tablet, powder for injection | ||
*Common Trade Names: Ceftin | *Dosage Strength: tablet: 250mg, 500mg; powder for injection: 750mg, 1.5g, 7.5g, 75g, 225g | ||
*Routes of Administration: PO, IV, IM | |||
*Common Trade Names: Ceftin, Zinacef | |||
==Adult Dosing== | ==Adult Dosing== | ||
===Mild-Moderate Bacterial infections=== | ===Mild-Moderate Bacterial infections=== | ||
*250- | *250-500mg PO BID x5-10 days | ||
===Steptococcal [[Pharyngitis]]/Tonsillitis=== | ===Steptococcal [[Pharyngitis]]/Tonsillitis=== | ||
* | *250mg PO BID x10 days | ||
===Acute [[Sinusitis|Maxillary Sinusitis]]=== | ===Acute [[Sinusitis|Maxillary Sinusitis]]=== | ||
* | *250mg PO BID x10 days; Info: not recommended per IDSA guidelines | ||
===Uncomplicated [[Gonococcal]] Infections=== | ===Uncomplicated [[Gonococcal]] Infections=== | ||
* | *1000mg PO x1; Info: for infections of cervix, urethra, rectum; dual treatment for chlamydial co-infection recommended | ||
===Early [[Lyme Disease]]=== | ===Early [[Lyme Disease]]=== | ||
* | *500mg PO BID x20 days | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*no adjustment; HD: give dose after dialysis, no supplement; PD: no supplement | *no adjustment; HD: give dose after dialysis, no supplement; PD: no supplement | ||
Line 22: | Line 24: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Mild-Moderate Bacterial Infections=== | ===Mild-Moderate Bacterial Infections=== | ||
*3 mo-12 yo: Dose: | *3 mo-12 yo: Dose: 30mg/kg/day susp PO divided q12h x10 days; Max: 1000mg/day; Alt: 250mg tab PO BID x10 days; Info: give susp with food | ||
*>13 yo: Dose: 250- | *>13 yo: Dose: 250-500mg tab PO BID x5-10 days; Info: dose, duration varies by infection type, severity | ||
===[[Otitis Media (Peds)|Acute Otitis Media]]=== | ===[[Otitis Media (Peds)|Acute Otitis Media]]=== | ||
*2 mo-5 yo Dose: | *2 mo-5 yo Dose: 30mg/kg/day susp PO divided q12h x10 days; Max: 1000mg/day; Alt: 250mg tab PO BID x10 days; Info: give susp with food | ||
*6-12 yo: Dose: | *6-12 yo: Dose: 30mg/kg/day susp PO divided q12h x5-10 days; Max: 1000mg/day; Alt: 250mg tab PO BID x5-10 days; Info: give susp with food | ||
===Acute Maxillary [[Sinusitis]]=== | ===Acute Maxillary [[Sinusitis]]=== | ||
*3 mo-12 yo: Dose: | *3 mo-12 yo: Dose: 30mg/kg/day susp PO divided q12h x10 days; Max: 1000mg/day; Alt: 250mg tab PO BID x10 days; Info: not recommended per IDSA guidelines; give susp with food | ||
*>13 yo: Dose: | *>13 yo: Dose: 250mg tab PO BID x10 days; Info: not recommended per IDSA guidelines | ||
===Streptococcal [[Pharyngitis]]/Tonsillitis=== | ===Streptococcal [[Pharyngitis]]/Tonsillitis=== | ||
*3 mo-12 yo: Dose: | *3 mo-12 yo: Dose: 20mg/kg/day susp PO divided q12h x10 days; Max: 500mg/day; Info: give with food | ||
*>13 yo: Dose: | *>13 yo: Dose: 250mg tab PO BID x10 days | ||
===Uncomplicated [[Gonococcal]] Infections=== | ===Uncomplicated [[Gonococcal]] Infections=== | ||
*adolescents: Dose: | *adolescents: Dose: 1000mg tab PO x1; Info: for infections of cervix, urethra, rectum; dual treatment for [[chlamydial]] co-infection recommended | ||
===Early [[Lyme Disease]]=== | ===Early [[Lyme Disease]]=== | ||
*>13 yo: Dose: | *>13 yo: Dose: 500mg tab PO BID x20 days | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*3 mo-12 yo: CrCl <10: | *3 mo-12 yo: CrCl <10: 15mg/kg PO susp q24h; HD: give dose after dialysis, no supplement; PD: no supplement | ||
*>13 yo: renal impairment: no adjustment; HD: give dose after dialysis, no supplement; PD: no supplement | *>13 yo: renal impairment: no adjustment; HD: give dose after dialysis, no supplement; PD: no supplement | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*not defined | *not defined | ||
==Special Populations== | ==Special Populations== | ||
*Pregnancy: | *Pregnancy: B | ||
*Lactation: | *Lactation: Probably Safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult: no adjustment; HD: give dose after dialysis, no supplement; PD: no supplement | ||
**Pediatric | **Pediatric: 3 mo-12 yo: CrCl <10: 15mg/kg susp q24h; HD: give dose after dialysis, no supplement; PD: no supplement; >13 yo: renal impairment: no adjustment; HD: give dose after dialysis, no supplement; PD: no supplement | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult: Not defined | ||
**Pediatric | **Pediatric: Not defined | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug (See [[Cephalosporin Cross-reactivity]]) | ||
*Caution if hypersensitive to [[PCN]] | |||
*Caution if renal impairment | |||
*Caution if hepatic impairment | |||
*Caution if seizure disorder | |||
*Caution if malnutrition | |||
*Caution if recent antibiotic-associated colitis history | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*[[Anaphylaxis]] | |||
*[[Angioedema]] | |||
*[[TEN|Toxic epidermal necrolysis]] | |||
*[[Stevens-Johnson Syndrome|Stevens-Johnson syndrome]] | |||
*Interstitial nephritis | |||
*Pancytopenia | |||
*[[Thrombocytopenia]] | |||
*Agranulocytosis | |||
*Leukopenia | |||
*Neutropenia | |||
*Hemolytic Anemia | |||
*[[Seizures]] | |||
*[[Clostridium difficile]] associated diarrhea | |||
===Common=== | ===Common=== | ||
*[[Diarrhea]] | |||
*Nausea/Vomiting | |||
*Jarisch-Herxheimer reaction | |||
*[[Vaginitis]] | |||
*Diaper Rash | |||
*ALT, AST elevated | |||
*Renal Impairment | |||
*Anemia | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 1.4 hours, 3.5 hours (CrCl 35), | ||
*Metabolism: | *Metabolism: Minimal; CYP 450: unknown | ||
*Excretion: | *Excretion: Urinary primarily (Up to 100% unchanged) | ||
*Mechanism of Action: | *Mechanism of Action: Bactericidal; inhibits cell wall mucopeptide synthesis | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | |||
{| class="wikitable" | |||
| align="center" style="background:#f0f0f0;"|'''Group''' | |||
| align="center" style="background:#f0f0f0;"|'''Organism''' | |||
| align="center" style="background:#f0f0f0;"|'''Sensitivity''' | |||
|- | |||
| Gram Positive||[[Strep. Group A, B, C, G]]||'''S''' | |||
|- | |||
| ||[[Strep. Pneumoniae]]||'''S''' | |||
|- | |||
| ||[[Viridans strep]]||'''S''' | |||
|- | |||
| ||Strep. anginosus gp||X1 | |||
|- | |||
| ||[[Enterococcus faecalis]]||R | |||
|- | |||
| ||[[Enterococcus faecium]]||X1 | |||
|- | |||
| ||[[MSSA]]||'''S''' | |||
|- | |||
| ||[[MRSA]]||R | |||
|- | |||
| ||[[CA-MRSA]]||R | |||
|- | |||
| ||[[Staph. Epidermidis]]||I | |||
|- | |||
| ||[[C. jeikeium]]||R | |||
|- | |||
| ||[[L. monocytogenes]]||R | |||
|- | |||
| Gram Negatives||[[N. gonorrhoeae]]||I | |||
|- | |||
| ||[[N. meningitidis]]||'''S''' | |||
|- | |||
| ||[[Moraxella catarrhalis]]||'''S''' | |||
|- | |||
| ||[[H. influenzae]]||'''S''' | |||
|- | |||
| ||[[E. coli]]||'''S''' | |||
|- | |||
| ||[[Klebsiella]] sp||'''S''' | |||
|- | |||
| ||E. coli/Klebsiella ESBL+||R | |||
|- | |||
| ||E coli/Klebsiella KPC+||R | |||
|- | |||
| ||[[Enterobacter]] sp, AmpC neg||I | |||
|- | |||
| ||[[Enterobacter]] sp, AmpC pos||R | |||
|- | |||
| ||[[Serratia]] sp||R | |||
|- | |||
| ||Serratia marcescens||X1 | |||
|- | |||
| ||[[Salmonella]] sp||X1 | |||
|- | |||
| ||[[Shigella]] sp||X1 | |||
|- | |||
| ||[[Proteus mirabilis]]||'''S''' | |||
|- | |||
| ||[[Proteus vulgaris]]||'''S''' | |||
|- | |||
| ||[[Providencia sp.]]||R | |||
|- | |||
| ||[[Morganella sp.]]||I | |||
|- | |||
| ||[[Citrobacter freundii]]||R | |||
|- | |||
| ||[[Citrobacter diversus]]||I | |||
|- | |||
| ||[[Citrobacter sp.]]||I | |||
|- | |||
| ||[[Aeromonas sp]]||'''S''' | |||
|- | |||
| ||[[Acinetobacter sp.]]||R | |||
|- | |||
| ||[[Pseudomonas aeruginosa]]||R | |||
|- | |||
| ||[[Burkholderia cepacia]]||R | |||
|- | |||
| ||[[Stenotrophomonas maltophilia]]||R | |||
|- | |||
| ||[[Yersinia enterocolitica]]||I | |||
|- | |||
| ||[[Francisella tularensis]]||X1 | |||
|- | |||
| ||[[Brucella sp.]]||X1 | |||
|- | |||
| ||[[Legionella sp.]]||R | |||
|- | |||
| ||[[Pasteurella multocida]]||'''S''' | |||
|- | |||
| ||[[Haemophilus ducreyi]]||X1 | |||
|- | |||
| ||[[Vibrio vulnificus]]||X1 | |||
|- | |||
| Misc||[[Chlamydophila sp]]||X1 | |||
|- | |||
| ||[[Mycoplasm pneumoniae]]||X1 | |||
|- | |||
| ||[[Rickettsia sp]]||X1 | |||
|- | |||
| ||[[Mycobacterium avium]]||X1 | |||
|- | |||
| Anaerobes||[[Actinomyces]]||X1 | |||
|- | |||
| ||[[Bacteroides fragilis]]||R | |||
|- | |||
| ||[[Prevotella melaninogenica]]||'''S''' | |||
|- | |||
| ||[[Clostridium difficile]]||X1 | |||
|- | |||
| ||[[Clostridium (not difficile)]]||'''S''' | |||
|- | |||
| ||[[Fusobacterium necrophorum]]||X1 | |||
|- | |||
| ||[[Peptostreptococcus sp.]]||'''S''' | |||
|} | |||
===Key=== | |||
{{Template:Antibacterial Spectra Key}} | |||
==See Also== | ==See Also== | ||
*[[Antibiotics (Main)]] | *[[Antibiotics (Main)]] | ||
== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | |||
[[Category: | [[Category:ID]] |
Latest revision as of 22:04, 19 September 2019
General
- Type: 2nd generation cephalosporin
- Dosage Forms: tablet, powder for injection
- Dosage Strength: tablet: 250mg, 500mg; powder for injection: 750mg, 1.5g, 7.5g, 75g, 225g
- Routes of Administration: PO, IV, IM
- Common Trade Names: Ceftin, Zinacef
Adult Dosing
Mild-Moderate Bacterial infections
- 250-500mg PO BID x5-10 days
Steptococcal Pharyngitis/Tonsillitis
- 250mg PO BID x10 days
Acute Maxillary Sinusitis
- 250mg PO BID x10 days; Info: not recommended per IDSA guidelines
Uncomplicated Gonococcal Infections
- 1000mg PO x1; Info: for infections of cervix, urethra, rectum; dual treatment for chlamydial co-infection recommended
Early Lyme Disease
- 500mg PO BID x20 days
Renal Dosing
- no adjustment; HD: give dose after dialysis, no supplement; PD: no supplement
Hepatic Dosing
- not defined
Pediatric Dosing
Mild-Moderate Bacterial Infections
- 3 mo-12 yo: Dose: 30mg/kg/day susp PO divided q12h x10 days; Max: 1000mg/day; Alt: 250mg tab PO BID x10 days; Info: give susp with food
- >13 yo: Dose: 250-500mg tab PO BID x5-10 days; Info: dose, duration varies by infection type, severity
Acute Otitis Media
- 2 mo-5 yo Dose: 30mg/kg/day susp PO divided q12h x10 days; Max: 1000mg/day; Alt: 250mg tab PO BID x10 days; Info: give susp with food
- 6-12 yo: Dose: 30mg/kg/day susp PO divided q12h x5-10 days; Max: 1000mg/day; Alt: 250mg tab PO BID x5-10 days; Info: give susp with food
Acute Maxillary Sinusitis
- 3 mo-12 yo: Dose: 30mg/kg/day susp PO divided q12h x10 days; Max: 1000mg/day; Alt: 250mg tab PO BID x10 days; Info: not recommended per IDSA guidelines; give susp with food
- >13 yo: Dose: 250mg tab PO BID x10 days; Info: not recommended per IDSA guidelines
Streptococcal Pharyngitis/Tonsillitis
- 3 mo-12 yo: Dose: 20mg/kg/day susp PO divided q12h x10 days; Max: 500mg/day; Info: give with food
- >13 yo: Dose: 250mg tab PO BID x10 days
Uncomplicated Gonococcal Infections
- adolescents: Dose: 1000mg tab PO x1; Info: for infections of cervix, urethra, rectum; dual treatment for chlamydial co-infection recommended
Early Lyme Disease
- >13 yo: Dose: 500mg tab PO BID x20 days
Renal Dosing
- 3 mo-12 yo: CrCl <10: 15mg/kg PO susp q24h; HD: give dose after dialysis, no supplement; PD: no supplement
- >13 yo: renal impairment: no adjustment; HD: give dose after dialysis, no supplement; PD: no supplement
Hepatic Dosing
- not defined
Special Populations
- Pregnancy: B
- Lactation: Probably Safe
- Renal Dosing
- Adult: no adjustment; HD: give dose after dialysis, no supplement; PD: no supplement
- Pediatric: 3 mo-12 yo: CrCl <10: 15mg/kg susp q24h; HD: give dose after dialysis, no supplement; PD: no supplement; >13 yo: renal impairment: no adjustment; HD: give dose after dialysis, no supplement; PD: no supplement
- Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
Contraindications
- Allergy to class/drug (See Cephalosporin Cross-reactivity)
- Caution if hypersensitive to PCN
- Caution if renal impairment
- Caution if hepatic impairment
- Caution if seizure disorder
- Caution if malnutrition
- Caution if recent antibiotic-associated colitis history
Adverse Reactions
Serious
- Anaphylaxis
- Angioedema
- Toxic epidermal necrolysis
- Stevens-Johnson syndrome
- Interstitial nephritis
- Pancytopenia
- Thrombocytopenia
- Agranulocytosis
- Leukopenia
- Neutropenia
- Hemolytic Anemia
- Seizures
- Clostridium difficile associated diarrhea
Common
- Diarrhea
- Nausea/Vomiting
- Jarisch-Herxheimer reaction
- Vaginitis
- Diaper Rash
- ALT, AST elevated
- Renal Impairment
- Anemia
Pharmacology
- Half-life: 1.4 hours, 3.5 hours (CrCl 35),
- Metabolism: Minimal; CYP 450: unknown
- Excretion: Urinary primarily (Up to 100% unchanged)
- Mechanism of Action: Bactericidal; inhibits cell wall mucopeptide synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014